On March 19, Algeria released the first batch of insulins from GEROPHARM pharmaceutical substance. The launch of production took place at the plant of the Algerian state pharmaceutical company “SAIDAL Industrial Group” in the presence of Nadia Bouabdella, Director of Pharmaceutical Production Department of the Ministry of Industry and Pharmaceutical Production of Algeria.
The first batch amounted to 40,000 vials of rapid-acting recombinant human insulin, while another 80,000 vials will be released by the end of the month. The entire volume of the medicinal product will be directed to the needs of the Algerian hospital sector.
According to IDF Diabetes Atlas, as of 2021, more than two million adult patients with diabetes mellitus have been registered in Algeria. At the same time, the proportion of residents with an undiagnosed disease is about 40 %.
Taking into account the scale of the spread of the disease and the importance of vital medicinal product availability for the patients, the President of Algeria instructed to provide 50 % of population’s needs in insulin by the end of 2023 at the expense of local production.
Russian pharmaceutical company GEROPHARM assisted in the operational solution of the task by transferring the technology of production of finished dosage forms of recombinant human insulins to the site of SAIDAL Group in Constantine. The audit of the plant and personnel training in Algeria and in Russia, at GEROPHARM R&D Centre, were carried out in record time: within 2 months. Among other capacities, the Algerian company’s specialists were given the methods of incoming inspection and release quality control.
Petr Rodionov, General Director of GEROPHARM: "Interest in Russian insulins from countries in Africa, Middle East, Asia and Latin America is growing every year. At the same time, we see the greatest prospects for GEROPHARM and our partners in the localisation of production. GEROPHARM already has a successful experience in implementing cooperation projects in this area.
With our Algerian partners, as well as with the invaluable assistance of the Russian Embassy and Trade Mission in Algeria, as well as the Algerian Embassy in Moscow, we managed to implement the first project for us to produce Russian insulin in Africa in the shortest possible time. I am sure that this will be an important step in the development of cooperation between our countries in the strategic area of pharmaceutical production.”
Fatoum Akasem, SAIDAL Group CEO: “Today we are especially proud to participate in the production of the first batch of human insulin at SAIDAL plant in the Algerian city of Constantine. This important milestone is the result of a close and effective cooperation between SAIDAL and GEROPHARM, whose success is based on rapid and efficient technology transfer.
Our partnership will not be limited to human insulin, but will also expand to other insulin products in the nearest future. This promising alliance embodies a real success story and opens up new opportunities for cooperation between Algeria and Russia in pharmaceutics.”
By the end of the year, SAIDAL industrial group and GEROPHARM plan to expand their cooperation on insulins.
SAIDAL Industrial Group is the first pharmaceutical company in Algeria to produce the generics. The group was founded in 1982 with the aim of building local pharmaceutical industry capable to guarantee the availability of medicinal products and to facilitate citizens’ access to treatment. Today, SAIDAL is an industrial group specialising in the development, production and commercialisation of pharmaceutical products for human use.